猪胆粉有效成分HDCA通过调控肠道胆汁酸代谢抑制胆固醇结石形成的实验研究

苏英洋 ,  邓妍 ,  刘星羽 ,  杜玉珍 ,  宁敏 ,  吴姗 ,  吴凯悦 ,  沈双

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (8) : 1016 -1026.

PDF (6948KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (8) : 1016 -1026. DOI: 10.12092/j.issn.1009-2501.2026.08.002
基础研究

猪胆粉有效成分HDCA通过调控肠道胆汁酸代谢抑制胆固醇结石形成的实验研究

作者信息 +

Experimental study on the inhibition of cholesterol gallstone forma- tion by HDCA, the active component of Pulvis Fellis Suis, through reg- ulation of intestinal bile acid metabolism

Author information +
文章历史 +
PDF (7114K)

摘要

目的: 探究猪去氧胆酸(hyodeoxycholic acid,HDCA)通过调控肠道胆汁酸代谢,影响法尼醇 X 受体(farnesoid X receptor,FXR)活性,抑制胆固醇结石生成。方法: 将 C57BL/6J 小鼠随机分成对照组、胆固醇结石模型组、猪胆粉(pulvis fellis suis,PFS)(7%、10%)给药干预组,每组 6 只;将 C57BL/6J 小鼠随机分成对照组、胆固醇结石模型组、HDCA(0.1%、0.5%、1%)给药干预组,每组 6 只;对各组小鼠进行称重、拍照、收集各组织样本并进行胆囊结石等级评估;用总胆固醇(T-CHO)检测试剂盒和酶标仪检测样本中总胆固醇的含量;在体外细胞实验方面,通过实时定量聚合酶链反应 (qPCR)分析 HDCA 对肠道细胞中 FXR 的直接调节作用;使用 16S 核糖体 RNA(16S ribosomal RNA,16S rRNA)测序技术检测各组小鼠粪便菌群的变化差异;液相色谱-质谱法(liquid chromatography-mass spectrometry, LC-MS/MS)测定回肠组织中胆汁酸池的变化。结果: 与模型组相比,10%PFS 和 1%HDCA 给药干预组均显著降低小鼠胆囊胆固醇结石等级和血清胆固醇含量(P<0.01),并且 1%HDCA 组显著降低小鼠肝重与体质量的比值和肝脏胆固醇含量(P<0.01);在体外实验中,HDCA 显著降低肠道细胞 Caco-2 中 FXR 的相对表达量 (P<0.05、P<0.01);HDCA 显著降低疣微菌门(Verrucomicrobiota 与激活 FXR 型胆汁酸呈显著正相关)的含量(P<0.05),显著升高拟杆菌门(Bacteroidota 与激活 FXR 型胆汁酸呈显著负相关)的含量(P<0.01);并且 HDCA 显著改变肠道胆汁酸成分,降低激活 FXR 型胆汁酸含量占比,升高抑制 FXR 型胆汁酸含量占比(P<0.05)。结论: HDCA 可能通过调节肠道菌群提高抑制 FXR 型胆汁酸的含量,从而间接发挥抑制肠道 FXR,促进胆汁酸合成且降低胆固醇饱和度的作用,达到抑制胆固醇结石形成的效果。

Abstract

AIM: To explore how hyodeoxycholic acid (HDCA) regulates intestinal bile acid metabolism and thereby modulates the activity of farnesoid X receptor (FXR) to inhibit the formation of cholesterol gallstones. METHODS: The C57BL/6J mice were randomly divided into a control group, a cholesterol gallstone model group, and a Pulvis fellis suis (PFS) (7%, 10%) administration intervention group (6 mice in each group). The C57BL/6J mice were also randomly divided into a control group, a cholesterol gallstone model group, and HDCA (0.1%, 0.5%, 1%) administration intervention groups (6 mice in each group). The mice in each group were weighed, photographed, and tissue samples were collected for gallstone grade assessment. The total cholesterol (T-CHO) content in the samples was detected using a total cholesterol detection kit and a microplate reader. In the in vitro cell experiments, the direct regulatory effect of HDCA on FXR in intestinal cells was analyzed by quantitative polymerase chain reaction (qPCR). The differences in fecal microbiota among the groups were detected using 16S ribosomal RNA (16S rRNA) sequencing technology. The changes in the bile acid pool in the ileum tissue were determined by liquid chromatography-mass spectrometry (LC-MS/MS). RESULTS: Compared with the model group, both the 10% PFS and 1% HDCA intervention groups significantly reduced the grade of cholesterol gallstones in the gallbladder and the serum cholesterol content of mice (P<0.01), and the 1% HDCA group significantly decreased the ratio of liver weight to body weight and the cholesterol content in the liver of mice (P<0.01); in the in vitro experiments, HDCA significantly reduced the relative expression level of FXR in intestinal cells Caco-2 (P<0.05,P<0.01); HDCA significantly reduced the content of theVerrucomicrobiota (which was significantly positively correlated with activated FXR-type bile acids) (P<0.05) and significantly increased the content of theBacteroidota (which was significantly negatively correlated with activated FXR-type bile acids) (P<0.01). Moreover, HDCA significantly changed the composition of intestinal bile acids, reducing the proportion of activated FXR-type bile acids and increasing the proportion of inhibitory FXR-type bile acids (P<0.05). CONCLUSION: HDCA may increase the inhibition of FXR-type bile acids by regulating the intestinal flora, thereby indirectly exerting the effect of inhibiting intestinal FXR, promoting bile acid synthesis and reducing cholesterol saturation, and achieving the goal of inhibiting the formation of cholesterol gallstones.

关键词

猪去氧胆酸 / 猪胆粉 / 法尼醇 X 受体 / 胆汁酸 / 胆固醇结石

Key words

hyodeoxycholic acid / Pulvis Fellis Suis / farnesoid X receptor / bile acids / cholesterol gallstones

引用本文

引用格式 ▾
苏英洋,邓妍,刘星羽,杜玉珍,宁敏,吴姗,吴凯悦,沈双. 猪胆粉有效成分HDCA通过调控肠道胆汁酸代谢抑制胆固醇结石形成的实验研究[J]. 中国临床药理学与治疗学, 2026, 31(8): 1016-1026 DOI:10.12092/j.issn.1009-2501.2026.08.002

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Wang X, Yu W, Jiang G, et al. Global epidemiology of gallstones in the 21st century: a systematic review and meta-analysis[J].Clin Gastroenterol Hepatol, 2024, 22(8): 1586-1595.

[2]

Stokes CS, Lammert F.Excess body weight and gallstone disease[J].Visc Med, 2021, 37(4): 254-260.

[3]

Song Y, Ma Y, Xie FC, et al. Age, gender, geographic and clinical differences for gallstones in China: a nationwide study[J].Ann Transl Med, 2022, 10(13): 735.

[4]

Lee SY, Jang SI, Cho JH, et al. Gallstone dissolution effects of combination therapy with n-3 polyunsaturated fatty acids and ursodeoxycholic acid: a randomized, prospective, preliminary clinical trial[J].Gut Liver, 2024, 18(6): 1069-1079.

[5]

Jazzar A, Raja K, Fasseeh ON, et al. Cost-effectiveness of S-adenosyl-l-methionine for intrahepatic cholestasis in the united arab emirates[J].Cureus, 2025, 17(6): e86124.

[6]

Luo D, Chen XP, Dai Y, et al. Cholecystectomy and risk of liver disease: a systematic review and meta-analysis of 27 million individuals[J].Int J Surg, 2023, 109(5): 1420-1429.

[7]

Kim SB, Kim KO, Kim TN.Prevalence and risk factors of gastric and colorectal cancer after cholecystectomy[J].J Korean Med Sci, 2020, 35(42): e354.

[8]

Wang HH, Portincasa P, Liu M, et al. Effects of biliary phospholipids on cholesterol crystallization and growth in gallstone formation[J].Adv Ther, 2023, 40(3): 743-768.

[9]

刘乃辉, 张超良, 张成全, 等. 溶解胆色素类结石的实验研究-Ⅰ、复方猪胆汁酸钠的溶石作用[J].新医学, 1981, 12(11): 563-565.

[10]

Sun YM, Kuang JL, Zhang HH, et al. Pig bile powder maintains blood glucose homeostasis by promoting glucagon-like peptide-1 secretion via inhibiting farnesoid X receptor[J].World J Diabetes, 2025, 16(6): 103616.

[11]

Zhang Y, Wei J, Li L, et al. Rapid identification of bear bile powder from other bile sources using chip-based nano-electrospray ionization tandem mass spectrometry[J].Rapid Commun Mass Spectrom, 2022, 36(15): e9326.

[12]

Zheng D, Zhang H, Zheng X, et al. Novel microbial modifications of bile acids and their functional implications[J].Imeta, 2024, 3(5): e243.

[13]

Song M, Yang Q, Zhang F, et al. Hyodeoxycholic acid (HDCA) suppresses intestinal epithelial cell proliferation through FXR-PI3K/AKT pathway, accompanied by alteration of bile acids metabolism profiles induced by gut bacteria[J].FASEB J, 2020, 34(5): 7103-7117.

[14]

Han Y, Guo X, Du H, et al. Modulation of bile acids and farnesoid X receptor by dietary Polysaccharides: Critical roles in health and disease[J].Trends Food Sci Technol, 2025, 162: 105075.

[15]

Akiyoshi T, Uchida K, Takase H, et al. Cholesterol gallstones in alloxan-diabetic mice[J].J Lipid Res, 1986, 27(9): 915-924.

[16]

Kuang J, Wang J, Li Y, et al. Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis[J].Cell Metab, 2023, 35(10): 1752-1766.

[17]

Chiang JYL, Ferrell JM.Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy[J].Am J Physiol Gastrointest Liver Physiol, 2020, 318(3): G554-G573.

[18]

汪静静, 彭景华, 刘毓, 等. 高脂高糖高胆固醇饮食联合四氯化碳诱导的代谢相关脂肪性肝炎小鼠模型肝脏胆汁酸谱的变化[J].临床肝胆病杂志, 2025, 41(4): 661-669.

[19]

Ridlon JM, Gaskins HR.Another renaissance for bile acid gastrointestinal microbiology[J].Nat Rev Gastroenterol Hepatol, 2024, 21(5): 348-364.

[20]

黄丹, 闫理姣, 万宛若, 等. 中药及其活性成分调节胆汁酸代谢抗动脉粥样硬化的研究进展[J].中草药, 2025, 56(11): 4069-4079.

[21]

Cai J, Rimal B, Jiang C, et al. Bile acid metabolism and signaling, the microbiota, and metabolic disease[J].Pharmacol Ther, 2022, 237: 108238.

[22]

雷榆, 胡亚欣, 余蕾, 等. 肝内胆汁淤积对小鼠回盲部胆汁酸谱及肠道菌群的影响[J].实用医学杂志, 2023, 39(10): 1232-1236.

[23]

Miao RR, Zhan S, Cui SX, et al. Intestinal aberrant sphingolipid metabolism shaped-gut microbiome and bile acids metabolome in the development of hepatic steatosis[J].FASEB J, 2022, 36(8): e22398.

[24]

李宛容, 陶梦婷, 邹元锋, 等. 黄精多糖通过调控结肠内胆汁酸代谢改善慢性阻塞性肺疾病模型小鼠的结肠损伤[J].中山大学学报 (医学科学版), 2025, 46(3): 431-443.

[25]

Yang WY, Chang PE, Li SJ, et al. Exploring bile-acid changes and microflora profiles in chicken fatty liver disease model[J].Animals (Basel), 2024, 14(7): 992.

[26]

Mohanty I, Allaband C, Mannochio-Russo H, et al. The changing metabolic landscape of bile acids - keys to metabolism and immune regulation[J].Nat Rev Gastroenterol Hepatol, 2024, 21(7): 493-516.

[27]

Chiang JYL, Ferrell JM.Discovery of farnesoid X receptor and its role in bile acid metabolism[J].Mol Cell Endocrinol, 2022, 548: 111618.

[28]

Xiao F, Gao X, Hu H, et al. Exclusive enteral nutrition exerts anti-inflammatory effects through modulating microbiota, bile acid metabolism, and immune activities[J].Nutrients, 2022, 14(21): 4463.

[29]

Hu W, Gong W, Yang F, et al. Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice[J].Int Immunopharmacol, 2025, 147: 113937.

[30]

Liu Y, Zhu J, Jin Y, et al. Disrupting bile acid metabolism by suppressing Fxr causes hepatocellular carcinoma induced by YAP activation[J].Nat Commun, 2025, 16(1): 3583.

[31]

Kumari A, Pathak DP, Asthana S. Bile acids mediated potential functional interaction between FXR and FATP5 in the regulation of lipid metabolism[J].Int J Biol Sci, 2020, 16(13): 2308-2322.

[32]

Xu Z, Huang Z, Zhang Y, et al. Farnesoid X receptor activation inhibits pancreatic carcinogenesis[J].Biochim Biophys Acta Mol Basis Dis, 2023, 1869(7): 166811.

[33]

许趁意, 岳仁宋, 吕雪莲, 等. 基于胆汁酸代谢轮廓研究半夏泻心汤通过 FXR/GLP-1 途径调控 2 型糖尿病血糖稳态的机制[J].中华中医药杂志, 2022, 37(8): 4394-4399.

[34]

Collins SL, Stine JC, Bisanz JE, et al. Bile acids and the gut microbiota: metabolic interactions and impacts on disease[J].Nat Rev Microbiol, 2023, 21(4): 236-247.

[35]

Katafuchi T, Makishima M.Molecular basis of bile acid-FXR-FGF15/19 signaling axis[J].Int J Mol Sci, 2022, 23(11): 6046.

[36]

段睿潇, 赵一帆, 叶永娟, 等. 胆汁酸代谢调节炎症性肠病的作用机制及药物研发[J].中国临床药理学与治疗学, 2022, 27(10): 1171-1181.

[37]

Watanabe S, Chen ZE, Fujita K, et al. Hyodeoxycholic acid (hdca) prevents development of dextran sulfate sodium (DSS)-induced colitis in mice: possible role of synergism between DSS and HDCA in increasing fecal bile acid levels[J].Biol Pharm Bull, 2022, 45(10): 1503-1509.

基金资助

国家自然科学基金项目(82200710)

上海健康医学院校院协同合作重点项目(XJJJ2503-6)

AI Summary AI Mindmap
PDF (6948KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉